The CANBACK trial : a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain
© 2021 AMPCo Pty Ltd..
OBJECTIVE: To assess the analgesic efficacy and safety of single-dose oral cannabidiol (CBD) as an adjunct to standard care for patients presenting to an emergency department with acute low back pain.
DESIGN: Randomised, double blinded, placebo-controlled clinical trial.
SETTING: The tertiary emergency department of Austin Hospital, Melbourne.
PARTICIPANTS: Patients who presented with acute, non-traumatic low back pain between 21 May 2018 and 13 June 2019.
INTERVENTION: One hundred eligible patients were randomised to receiving 400 mg CBD or placebo in addition to standard emergency department analgesic medication.
MAIN OUTCOME MEASURES: Pain score two hours after administration of study agent, on a verbal numerical pain scale (range, 0-10). Secondary outcomes were length of stay, need for rescue analgesia, and adverse events.
RESULTS: The median age of the 100 participants was 47 years (IQR, 34-60 years); 44 were women. Mean pain scores at two hours were similar for the CBD (6.2 points; 95% CI, 5.5-6.9 points) and placebo groups (5.8 points; 95% CI, 5.1-6.6 points; absolute difference, -0.3 points; 95% CI, -1.3 to 0.6 points). The median length of stay was 9.0 hours (IQR, 7.4-12 hours) for the CBD group and 8.5 hours (IQR, 6.5-21 hours) for the placebo group. Oxycodone use during the four hours preceding and the four hours after receiving CBD or placebo was similar for the two groups, as were reported side effects.
CONCLUSION: CBD was not superior to placebo as an adjunct medication for relieving acute non-traumatic low back pain in the emergency department.
TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry, ACTRN12618000487213 (prospective).
| Errataetall: |
CommentIn: Med J Aust. 2021 May;214(8):360-361. - PMID 33846981 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:214 |
|---|---|
| Enthalten in: |
The Medical journal of Australia - 214(2021), 8 vom: 13. Mai, Seite 370-375 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bebee, Bronwyn [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
19GBJ60SN5 |
|---|
| Anmerkungen: |
Date Completed 12.05.2021 Date Revised 12.05.2021 published: Print-Electronic CommentIn: Med J Aust. 2021 May;214(8):360-361. - PMID 33846981 Citation Status MEDLINE |
|---|
| doi: |
10.5694/mja2.51014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324019718 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324019718 | ||
| 003 | DE-627 | ||
| 005 | 20231225185427.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5694/mja2.51014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1080.xml |
| 035 | |a (DE-627)NLM324019718 | ||
| 035 | |a (NLM)33846971 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bebee, Bronwyn |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The CANBACK trial |b a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.05.2021 | ||
| 500 | |a Date Revised 12.05.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Med J Aust. 2021 May;214(8):360-361. - PMID 33846981 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 AMPCo Pty Ltd. | ||
| 520 | |a OBJECTIVE: To assess the analgesic efficacy and safety of single-dose oral cannabidiol (CBD) as an adjunct to standard care for patients presenting to an emergency department with acute low back pain | ||
| 520 | |a DESIGN: Randomised, double blinded, placebo-controlled clinical trial | ||
| 520 | |a SETTING: The tertiary emergency department of Austin Hospital, Melbourne | ||
| 520 | |a PARTICIPANTS: Patients who presented with acute, non-traumatic low back pain between 21 May 2018 and 13 June 2019 | ||
| 520 | |a INTERVENTION: One hundred eligible patients were randomised to receiving 400 mg CBD or placebo in addition to standard emergency department analgesic medication | ||
| 520 | |a MAIN OUTCOME MEASURES: Pain score two hours after administration of study agent, on a verbal numerical pain scale (range, 0-10). Secondary outcomes were length of stay, need for rescue analgesia, and adverse events | ||
| 520 | |a RESULTS: The median age of the 100 participants was 47 years (IQR, 34-60 years); 44 were women. Mean pain scores at two hours were similar for the CBD (6.2 points; 95% CI, 5.5-6.9 points) and placebo groups (5.8 points; 95% CI, 5.1-6.6 points; absolute difference, -0.3 points; 95% CI, -1.3 to 0.6 points). The median length of stay was 9.0 hours (IQR, 7.4-12 hours) for the CBD group and 8.5 hours (IQR, 6.5-21 hours) for the placebo group. Oxycodone use during the four hours preceding and the four hours after receiving CBD or placebo was similar for the two groups, as were reported side effects | ||
| 520 | |a CONCLUSION: CBD was not superior to placebo as an adjunct medication for relieving acute non-traumatic low back pain in the emergency department | ||
| 520 | |a TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry, ACTRN12618000487213 (prospective) | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Acute pain | |
| 650 | 4 | |a Back pain | |
| 650 | 4 | |a Medical marijuana | |
| 650 | 7 | |a Placebos |2 NLM | |
| 650 | 7 | |a Cannabidiol |2 NLM | |
| 650 | 7 | |a 19GBJ60SN5 |2 NLM | |
| 650 | 7 | |a Acetaminophen |2 NLM | |
| 650 | 7 | |a 362O9ITL9D |2 NLM | |
| 650 | 7 | |a Ibuprofen |2 NLM | |
| 650 | 7 | |a WK2XYI10QM |2 NLM | |
| 700 | 1 | |a Taylor, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Bourke, Elyssia |e verfasserin |4 aut | |
| 700 | 1 | |a Pollack, Kimberley |e verfasserin |4 aut | |
| 700 | 1 | |a Foster, Lian |e verfasserin |4 aut | |
| 700 | 1 | |a Ching, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Anselm |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Medical journal of Australia |d 1945 |g 214(2021), 8 vom: 13. Mai, Seite 370-375 |w (DE-627)NLM000007927 |x 1326-5377 |7 nnns |
| 773 | 1 | 8 | |g volume:214 |g year:2021 |g number:8 |g day:13 |g month:05 |g pages:370-375 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5694/mja2.51014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 214 |j 2021 |e 8 |b 13 |c 05 |h 370-375 | ||